MARKET

RDY

RDY

Dr.Reddys
NYSE

Real-time Quotes | Nasdaq Last Sale

61.30
-0.48
-0.78%
After Hours: 61.44 +0.14 +0.23% 17:40 03/05 EST
OPEN
60.99
PREV CLOSE
61.78
HIGH
61.53
LOW
60.30
VOLUME
263.47K
TURNOVER
--
52 WEEK HIGH
73.50
52 WEEK LOW
33.33
MARKET CAP
10.17B
P/E (TTM)
48.47
1D
5D
1M
3M
1Y
5Y
U.S. Moves to Protect Tech Supply Chains. Why Taiwan and Korea Play an Important Part.
The dominant companies in semiconductors and advanced batteries are in Taiwan and South Korea. That’s a challenge for Washington, and an opportunity for emerging markets investors.
Barrons.com · 1d ago
DJ U.S. Moves to Protect Tech Supply Chains. Why Taiwan and Korea Play an Important Part. -- Barrons.com
Dow Jones · 2d ago
Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid
Zacks.com · 02/26 14:47
Dr. Reddy's requested by India to give more data for Sputnik V approval
The Indian drug regulator has asked Dr. Reddy's Laboratories ([[RDY]] +1.3%) to provide more data regarding its application seeking the emergency use approval for Sputnik V, the coronavirus vaccine developed by Russia.Following
Seekingalpha · 02/25 16:07
BRIEF-Dr.Reddy's Labs Launches Lansoprazole DR Orally Disintegrating Tablets In U.S.
reuters.com · 02/22 11:00
Dr. Reddy's launches generic Prevacid SoluTab tablets in U.S.
Dr. Reddy’s Laboratories (RDY) announces the launch of Lansoprazole DR Orally Disintegrating Tablets, a therapeutic equivalent generic version of Takeda Pharma's Prevacid SoluTab Delayed-Release Orally Disintegrating Tablets, 15 mg and
Seekingalpha · 02/22 08:06
Dr. Reddy's Laboratories Announces the Launch of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced the launch of Lansoprazole DR Orally Disintegrating Tablets, a therapeutic equivalent ...
Business Wire · 02/22 06:13
Dr. Reddy's Launches Generic Prevacid in US
MT Newswires · 02/22 04:32
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RDY. Analyze the recent business situations of Dr.Reddys through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RDY stock price target is 72.50 with a high estimate of 74.99 and a low estimate of 70.00.
EPS
Institutional Holdings
Institutions: 254
Institutional Holdings: 21.03M
% Owned: 12.67%
Shares Outstanding: 165.94M
TypeInstitutionsShares
Increased
47
732.16K
New
38
-331.41K
Decreased
77
2.88M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
Satish Reddy
Co-Chairman/Managing Director/Director
G. Prasad
Chief Executive Officer
Erez Israeli
Corporate Executive
MARC KIKUCHI
Chief Financial Officer
Parag Agarwal
Corporate Executive
Patrick Aghanian
Corporate Executive
Marc Kikuchi
Corporate Executive
M. Ramana
Chief Human Resource Officer
Archana Bhaskar
Other
Raymond De Vre
Other
Sauri Gudlavalleti
Other
Ganadhish Kamat
Other
Anil Namboodiripad
Other
YUGANDHAR PUVVALA
Other
Yugandhar Puvvala
Other
Deepak Sapra
Other
SANJAY SHARMA
Other
Sanjay Sharma
Secretary
Sandeep Poddar
Non-Executive Independent Director
Bruce Carter
Non-Executive Independent Director
Bharat Doshi
Non-Executive Independent Director
Sridar Iyengar
Non-Executive Independent Director
Prasad Menon
Non-Executive Independent Director
Kalpana Morparia
Non-Executive Independent Director
Allan Oberman
Non-Executive Independent Director
Leo Puri
Non-Executive Independent Director
Shikha Sharma
Declaration Date
Dividend Per Share
Ex-Div Date
06/26/2020
Dividend USD 0.2769603
07/10/2020
--
Dividend USD 0.262229
07/12/2019
--
Dividend USD 0.272
07/13/2018
08/04/2017
Dividend USD 0.294
07/13/2017
08/03/2016
Dividend USD 0.279
07/14/2016
08/11/2015
Dividend USD 0.293
07/08/2015
08/08/2014
Dividend USD 0.272
08/01/2014
--
Dividend USD 0.283
07/09/2014
08/08/2013
Dividend USD 0.225
07/10/2013
  • All
  • Financials
  • Insiders
More
About RDY
Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.

Webull offers kinds of Dr.Reddy's Laboratories Ltd (ADR) stock information, including NYSE:RDY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDY stock methods without spending real money on the virtual paper trading platform.